
Pharmacy Practice in Focus: Oncology
- August 2020
- Volume 2
- Issue 4
CE: Advanced Melanoma: A Pharmacist’s Guide to Treatment and Patient Management for New and Emerging Drug Therapies
This activity is supported by an educational grant from Merck Sharp & Dohme Corp..
This activity is supported by an educational grant from Merck Sharp & Dohme Corp..
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Explain how genetic mutations and biomarkers influence therapy selection for the treatment of cutaneous melanoma
- Identify appropriate adjuvant therapy for the treatment of a patient with cutaneous melanoma based on patient- and disease-specific factors
- Examine guideline recommendations to appropriately place targeted therapies in a patient’s treatment algorithm for advanced melanoma
- Identify strategies that pharmacists can employ to overcome challenges commonly seen in the management of patients with advanced melanoma
FACULTY
Heather Armbruster, PharmD, BCOP
Specialty Practice Pharmacist, Melanoma
The Ohio State University , James Comprehensive Cancer Center, Columbus, Ohio
TARGET AUDIENCE: Oncology, health-system, and specialty pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: August 14, 2020
EXPIRATION DATE: February 14, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
about 5 years ago
Managing Oral Oncolytics During the COVID-19 Pandemicabout 5 years ago
Brown Bag Consult®: Chemotherapy Recovery With Heart Problemsabout 5 years ago
Apixaban: A New Treatment Option for Cancer-Associated VTEabout 5 years ago
An Overview of CAR T-Cell Therapies and Adverse Effectsabout 5 years ago
What Does Excellence in Oncology Pharmacy Look Like?about 5 years ago
Stability of Rare TP53 Comutations in Patients With AMLNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.